Clinical Trial Update: Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) [Phase 3]

View source ↗

Summary

Phase 3 trial NCT06393374 evaluates Sacituzumab govitecan with pembrolizumab versus treatment of physician's choice in triple-negative breast cancer patients wh…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Triple-Negative Breast Cancer | Phase 3 | Status: RECRUITING